Among novel bis-nucleobase-phenanthridinium conjugates bis-uracil analogue stabilized significantly more effective poly-dA-poly-dT and poly-AH(+)-poly-AH(+) than adenine analogue and reference compound . For the alternating poly-dAdT-poly-dAdT however, the binding preference is lost, pointing to the importance of specific interactions of uracils of with homopolynucleotides containing consecutive adenines.
A set of (p-cymene)-ruthenium amino acid bioconjugates 1 and 2 is reported.The bioconjugates 2 show micromolar affinity for proteins.Increased potency and selectivity of 2 towards cancer cell lines is detected.The cytotoxicity of bioconjugates 2 is in correlation with their BSA binding constants.Cell stress response includes increase of cells in S phase of cell cycle, induction of autophagy and use of GSH as detoxification mechanism.
Among series of novel bis-phenanthridinium -nucleobase conjugates, the adenine derivative revealed high (logKs = 6.9 M -1 ) and selective affinity toward complementary nucleotide (UMP), accompanied by specific change in the UV/Vis spectrum of phenanthridine subunits, differing significantly from changes caused by addition of other nucleotides. High stability and selectivity of adenine-conjugate/UMP non-covalent complex is according to the molecular modelling studies correlated to the number of inter-and intramolecular aromatic stacking interactions between phenanthridinium subunits, covalently attached adenine and added UMP, while selectivity of adenine-conjugate toward UMP in respect to other nucleotides is most likely the consequence of additional hydrogen bonding between UMP and adenine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.